Safety under the regulatory spotlight — 200 documents in 90 days

77 documents in the last 30 days alone

This concentration of documents around safety may indicate a tightening cycle, particularly if the recent surge reflects more guidance, enforcement emphasis, or updated expectations on signal detection, labeling, and postmarketing surveillance. Sponsors should consider that regulators may be sharpening their focus on benefit-risk narratives and the quality of safety datasets, so companies with active safety programs should watch for shifts in pharmacovigilance standards, expedited reporting expectations, and any new emphasis on real-world evidence or risk management plans.